Insider · CIK 0001606302
Rachel McMinn
Files at NGNE (Neurogene Inc.). First filing Nov 25, 2024, latest Mar 30, 2026.
Rachel McMinn files SEC Form 4 as CEO and director at NGNE (Neurogene Inc.). Since Nov 25, 2024, Rachel McMinn has reported 1 open-market buy worth $969k and 1 open-market sell worth $74k, the latest filed on Mar 30, 2026.
A track record needs three past buys with six months of prices behind them; Rachel McMinn has 1, so none is measured yet.
The newest scored trade: sold $74k of NGNE on Mar 26, 2026, filed Mar 30, 2026, scored 28 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $74k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NGNE: Neurogene Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Neurogene Inc. | $74k 3,352 shares | -0% | +192% from low-38% from high | |
| 65Notable | Neurogene Inc. | $969k 47,500 shares | +4% | - |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | NGNE Neurogene Inc. | MOption exercise Common Stock | +756 | $25.32 | $19k | 1,345,063 | 11 d ago |
| Sep 22, 2026 | NGNE Neurogene Inc. | MOption exercise Stock Option (Right to Buy)derivative | -756 | $0.00 | $0 | 0 | 11 d ago |
| Mar 26, 2026 | NGNE Neurogene Inc. | SOpen-market sale Common Stock10b5-1 | -3,352 | $22.07 | $74k | 1,344,307 | Mar 30, 2026 |
| Feb 20, 2026 | NGNE Neurogene Inc. | AGrant or award Common Stock | +25,900 | $0.00 | $0 | 1,347,659 | Feb 24, 2026 |
| Feb 20, 2026 | NGNE Neurogene Inc. | AGrant or award Stock Option (Right to Buy)derivative | +155,100 | $0.00 | $0 | 155,100 | Feb 24, 2026 |
| Nov 22, 2024 | NGNE Neurogene Inc. | POpen-market purchase Common Stock | +47,500 | $20.40 | $969k | 1,297,859 | Nov 25, 2024 |
Questions about Rachel McMinn
Answered from the filings on this page, as of the latest one.
Is Rachel McMinn buying or selling?
In the last 12 months Rachel McMinn reported 0 open-market buys worth $0 and 1 open-market sell worth $74k on SEC Form 4; the latest was sold $74k of NGNE on Mar 26, 2026. Grants, option exercises and tax withholding are not counted.
How did Rachel McMinn's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Rachel McMinn has 1.
Where does Rachel McMinn file Form 4?
Rachel McMinn has filed Form 4 at NGNE (Neurogene Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.